Ascribe Bioscience, an Ithaca, NY–based agricultural technology company, has closed a $12 million Series A financing round to support the commercial launch of its flagship biofungicide, Phytalix®. The funding will accelerate manufacturing and early commercialization ahead of regulatory approval in Brazil, with U.S. and other markets to follow. Founded in 2017 on research from the Boyce Thompson Institute at Cornell University, Ascribe develops disease control solutions from soil microbiome–derived small molecules that help farmers grow more resilient, higher-yielding crops. Through the NSF I-Corps program, Ascribe identified row crop farmers as a priority customer segment and built industry relationships that have helped drive its growth.
